The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients

Kenji Taketani, Eriko Tokunaga, Nami Yamashita, Kimihiro Tanaka, Sayuri Akiyoshi, Satoko Okada, Koji Ando, Yasue Kimura, Hiroshi Saeki, Eiji Oki, Masaru Morita, Tetsuya Kusumoto, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Purpose: It is important for patients to complete the planned hormone therapy to reduce both the recurrence and mortality rates of hormone receptor-positive breast cancer. We investigated the rates and factors related to the early discontinuation of adjuvant hormone therapy at our institution.

Methods: We identified 145 females prescribed adjuvant hormone therapy who were followed up for longer than 5 years. The rate of completing the planned hormone therapy and factors related to early discontinuation were examined. The relapse-free survival rate was examined between the completion group and the discontinuation group.

Results: The completion rate was 90.6 %. The primary reason for discontinuing hormone therapy within 5 years was side effects, such as arthritic pain. The primary factor related to early discontinuation was a significantly younger age. The relapse-free survival rate was significantly lower in the discontinuation group (p = 0.025).

Conclusions: More than 90 % of the patients completed the planned adjuvant hormone therapy, and early discontinuation was related to a shorter RFS. To improve the rate of the successful completion of adjuvant hormone therapy, it is important to provide supportive care to reduce the occurrence of side effects and to care for young females with a desire to become pregnant.

Original languageEnglish
Pages (from-to)1841-1846
Number of pages6
JournalSurgery today
Volume44
Issue number10
DOIs
Publication statusPublished - Oct 2014

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint

Dive into the research topics of 'The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients'. Together they form a unique fingerprint.

Cite this